Mumbai, Feb. 19 -- The inspection was conducted from 9th February to 18th February 2026. At the end of the inspection, a 'Form 483' was issued with 2 observations and the company said that it will respond to the US FDA within the stipulated timelines.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

The company's consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.

Published by HT Digital Content Services with permission from Capital Market....